Beschreibung:
<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim and Objective</jats:title><jats:p>We sought to investigate and compare outcomes 2 years after Hybrid‐stenting with bioresorbable vascular scaffolds (BVS) and contemporary metallic drug‐eluting stents (DES) within the same coronary lesion versus BVS alone.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Between 11/2012 and 7/2015 at our institution, 134 (33.2%) were treated with Hybrid‐stenting for complex or long coronary lesions, 270 patients were treated by BVS alone. The primary outcome of interest was target lesion failure (TLF) at 2‐years of follow‐up.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients treated by Hybrid‐stenting were more frequently men (80% vs. 70%, p = 0.04) had extensive multivessel disease (84% vs. 71%, p < 0.01) including more complex (89% vs. 52%, p < 0.01) and longer lesions (28.9 mm vs 16.4 ± mm, p < 0.01) resulting in longer treated segments (47.3 mm vs 21.5 mm, p < 0.01) and more residual in‐segment stenosis (12.3% vs 8.5%, p < 0.01) compared to BVS alone patients. At 2 years, cumulative incidence of TLF was 9.7% of Hybrid‐stenting patients and 11.5% of BVS alone patients (p = 0.62), myocardial infarction (3.0% vs 4.1%, p = 0.59) and mortality (1.5% vs 4.1%, p = 0.17), respectively.</jats:p><jats:p>Target lesion revascularization occurred in 9 Hybrid‐stenting patients (2 located in DES) and in 20 BVS alone patients, cumulative incidence 6.7% vs. 7.4% (p = 0.80). Chronic kidney disease and residual in‐segment stenosis >30% were identified as independent predictors of TLF at 2‐years.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Despite differences in clinical and angiographic profile, Hybrid‐stenting performed similar to BVS alone at 2 years after percutaneous coronary intervention.</jats:p></jats:sec>